A comparison of local and systemic acyclovir in the management of herpetic disciform keratitis

S M Porter, A Patterson, P Kho

Abstract

Forty-three patients with active herpetic disciform keratitis were entered into an open study to compare the efficacy of oral acyclovir (400 mg) with acyclovir ophthalmic ointment (3%) to inhibit viral replication during treatment with 0-05% prednisolone eye drops. All patients, regardless of the mode of therapy, were treated five times a day until they were healed. The mean time to heal in the oral group was 25-9 days and in the topical group was 25-3 days. Resolution of lacrimation was significantly faster in the oral group (12-1 days versus 27-6 days). The patients on tablets also showed a greater improvement in visual acuity. No statistically significant differences were found between the two groups in the incidence of recurrences over a three-year post-treatment period. It is concluded that oral acyclovir treatment is an effective alternative to ophthalmic ointment in the management of herpetic disciform keratitis.

The pathogenesis of herpetic disciform keratitis is not fully understood, but the disease may be the result of a delayed hypersensitivity reaction to viral replication in the corneal stroma. In moderate and severe disease the use of local steroids with an antiviral therapy is justified. The use of steroids alone can result in a high complication rate of dendritic ulceration, and the use of an antiviral agent alone has been shown to be inadequate.

Acyclovir is a potent and selective inhibitor of herpes simplex virus replication. When administered topically it is well tolerated and effective for the treatment of dendritic keratitis. It has also been used successfully for the treatment of disciform keratitis when combined with betamethasone. Therapeutic concentrations within the eye can be attained by local or systemic administration. This study compares local and systemic treatment with acyclovir in a group of patients suffering from active herpetic disciform keratitis to ascertain firstly whether the route of application favourably affects the outcome of active disease, and secondly whether there is any significant difference in subsequent recurrence rates. All patients received local dilute steroids.

Methods and materials

Patients aged 18 years and over with a clinical diagnosis of either primary or recurrent disciform keratitis were entered into this open, randomised comparative study over a period of three years. The diagnosis was based on clinical appearance and history. Patients were excluded if they had been treated with specific antiviral therapy within the previous 14 days or with topical or systemic steroids within the previous 30 days. Patients with active epithelial disease, renal function impairment, or of child bearing potential were also excluded. Informed consent was obtained.

All patients applied prednisolone (0-05%) eye drops five times daily to the affected eye. In addition the patients were randomly allocated to one of two treatment groups. One group received acyclovir ointment (3%) and the other group received acyclovir tablets (400 mg). Both medications were administered at four-hourly intervals, but patients omitted the dose if the middle of the night. They were treated until healing was evident. When the keratitis had resolved, acyclovir treatment was terminated and the steroid dosage was gradually tapered over a one-month period. Mydriatics and glaucoma therapy were given as necessary.

The patients were followed up as often as clinically necessary but at least weekly during treatment and then at 1, 3, 6, and 12 months. Patients were then seen at yearly intervals when possible.

On entry and on subsequent visits the severity of pain, photophobia, lacrimation, and grittiness sensation was assessed on a 0-3 score, where 0 = none, 1 = mild, 2 = moderate, 3 = severe. A full ocular examination was also carried out with a slit-lamp biomicroscope. Assessments included the severity of conjunctivitis (redness, scarring, follicles), extent of stromal oedema and infiltration, disturbances in Descemet’s membrane, presence and extent of uveitis, and presence of endothelial cells and keratic precipitates. The visual acuity of the affected eye (uncorrected and with pinhole) was assessed by means of the Snellen chart. Intraocular pressure was measured by a tonometer. Any signs or symptoms potentially attributable to acyclovir administration were recorded.

TABLE I Patient demography

<table>
<thead>
<tr>
<th>Tablet recipients</th>
<th>Ointment recipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of eval. patients</td>
<td>20</td>
</tr>
<tr>
<td>No. of females</td>
<td>10</td>
</tr>
<tr>
<td>No. of males</td>
<td>10</td>
</tr>
<tr>
<td>Mean age (SD) in years</td>
<td>56.3 (17.8-86)</td>
</tr>
<tr>
<td>% Patients with previous disciform keratitis</td>
<td>50</td>
</tr>
<tr>
<td>% Patients with previous cutaneous herpes</td>
<td>63-2</td>
</tr>
<tr>
<td>% Patients received previous antiviral therapy</td>
<td>83-3</td>
</tr>
<tr>
<td>% Patients received previous steroid therapy</td>
<td>75-0</td>
</tr>
<tr>
<td>No. of patients using concomitant medication</td>
<td>15</td>
</tr>
<tr>
<td>No. of patients receiving antiglaucoma therapy</td>
<td>6</td>
</tr>
</tbody>
</table>

SD = standard deviation.
Patients were withdrawn from the trial if there were signs of increased inflammatory activity or if their condition remained static for 14 days.

The main criteria for assessing healing were the absence of stromal oedema, ciliary injection, and keratic precipitates. The times to resolution of individual signs and symptoms and also of healing were analysed by the Mantel-Cox test as applied by the BMDP statistical package. Unaided Snellen visual acuity was used in the analysis except in patients who had been given mydriatics, when a pinhole was used. Visual acuity scores on entry, changes in visual acuity from entry, and changes in intraocular pressure from entry between the two groups were compared by Student's t test. Recurrence rates were analysed by the Pearson χ² test. p Values of ≤0.05 were considered statistically significant.

Results

Patient Demography

Forty-three patients entered the study. Two patients failed retrospectively to meet the entry criteria and two defaulted during the study. The remaining 39 patients were entered. Of these patients 19 received acyclovir ophthalmic ointment and 20 received acyclovir tablets. Table I shows the patient demography for each treatment group.

Resolution of Symptoms and Signs

The rates of resolution of the clinical symptoms of pain, photophobia, and grittiness were not significantly different between the two treatment groups. However, resolution of lacrimation was significantly faster in the oral group, with a mean of 12.1 days for the tablet recipients and 27.6 days for the ointment recipients (p=0.02).

The mean times to resolution of conjunctivitis (redness, scarring, and follicles), stromal infiltration, stromal oedema, disturbances in Descemet's membrane, and uveitis were not statistically different between tablet recipients and the ointment recipients (p>0.15, Table II).

Complete healing was observed in patients on tablets in a mean time of 25.9 days and in the ointment group in a mean time of 25.3 days. This difference was not statistically significant (p>0.05, Fig 1). An average decrease in intraocular pressure of 4.6 mmHg was noted among patients receiving oral acyclovir, and an average decrease of 4.1 mmHg was noted among patients receiving ophthalmic ointment. This difference was also not statistically significant.

The median visual acuity scores on entry for the two treatment groups were comparable (p>0.05), and were 6/24 (0.25) for the tablet recipients and 6/36 (0.17) for the ointment recipients. The mean change in visual acuity from entry was 0.13 in the ointment group, and 0.28 in the tablet group (p=0.02). Thus there was a significantly greater improvement in vision between entry and the end of treatment in the tablet group.

Both acyclovir ointment and tablets were well tolerated. Two patients receiving acyclovir ointment had punctate epithelial keratopathy which persisted throughout the treatment period but cleared immediately on stopping the medication. No adverse reactions were reported by patients receiving acyclovir tablets.

Recurrences During the Follow-Up

Table III summarises the recurrences of disciform keratitis for each treatment group. Attempts were made to follow up the patients for a maximum of three years. One patient died during the first year of follow-up, one in the second year, and three in the third year. None of these deaths was associated with recurrences or with acyclovir treatment. No significant difference was found between the recurrence rates in the two treatment groups.

Two patients in the ointment group underwent penetrating keratoplasty, one in the first year and one in the second year. Both progressed well and have not suffered any postoperative recurrence.

In the ointment group one patient developed a dendritic ulcer six months after healing. In the oral group three patients each developed one dendritic ulcer at three months, six months, and 12 months. No patient developed a dendritic ulcer during the period of treatment, and in particular none occurred during the month of unprotected reducing-dose steroid therapy. Trophic ulcers occurred in both treatment groups, but there was no difference in frequency between the two groups.

Discussion

No statistically significant differences were...
The incidence of recurrent attacks of disciform keratitis in each year of follow-up is shown in Table III. The table shows that the incidence of recurrent attacks was highest in the first year of follow-up and decreased in subsequent years. The incidence of recurrent attacks was similar between the tablet and ointment groups, with no statistically significant difference between the groups.

The mean age of the patients was 57.4 years, and the mean duration of symptoms was 14 days. The majority of patients had unilateral disease, with 62.5% having unilateral disease and 37.5% having bilateral disease.

The facial nerve was involved in 50% of cases, and the lacrimal gland was involved in 12.5% of cases. The majority of patients had a history of facial paralysis or facial weakness, with 75% of patients having a history of facial paralysis or facial weakness.

The treatment of choice for recurrent disciform keratitis was topical acyclovir, with 87.5% of patients receiving topical acyclovir. In the tablet group, the median time to resolution of symptoms was 3 weeks, and in the ointment group, the median time to resolution of symptoms was 4 weeks. The difference in the median time to resolution of symptoms between the two groups was not statistically significant.

The authors conclude that topical acyclovir is effective in the treatment of recurrent disciform keratitis and that the choice of formulation (tablet or ointment) does not significantly affect the outcome of treatment.

The study was supported by Wellcome Research Laboratories.

A comparison of local and systemic acyclovir in the management of herpetic disciform keratitis.
S. M. Porter, A. Patterson and P. Kho

doi: 10.1136/bjo.74.5.283

Updated information and services can be found at:
http://bjo.bmj.com/content/74/5/283

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/